Trials / Completed
CompletedNCT01831505
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Presage Biosciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph nodes in situ respond to standard of care therapeutics precisely microinjected with the CIVO(tm) microdosing system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2013-04-15
- Last updated
- 2017-02-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01831505. Inclusion in this directory is not an endorsement.